@article {64949,
	title = {Epidemiological Study on β-Thalassemia in Algeria},
	journal = {BloodBlood},
	volume = {132},
	year = {2018},
	month = {2018},
	pages = {4902},
	abstract = {Introduction :\&nbsp;Among genetic diseases in hematology, β Thalassemia ranks second after sickle cell disorders in Algeria. Given the seriousness and cost of the care that arises, a national action plan is needed. As a starting point, a national survey is essential to know the epidemiological situation of this disease. Objective :\&nbsp;To determine the soci-demographic, diagnosis and evolution characteristics of major and intermediate thalassemia in Algeria. Materiels and Methods :\&nbsp;This is a multicenter, retrospective, analytical study of 775 patients with thalassemia major (TM: 598 cases) and intermediate (TI: 177 cases). This national survey is representative of 21 services (Hematology: 19, Pediatrics: 03). The data was collected from medical records on a survey card distributed to all relevant services. Results :\&nbsp;As of January 1, 2017, the prevalence of β Thalassemia estimated from this study is of the order of 3.47 cases per 100 000 inhabitants. The current average age of major thalassemia (MT) is 17.90 years, with extremes of [1-44 years], that of intermediate form (IT) is 23 years old with extremes of [1-61 years], the sex ratio is 1.15. The concept of consanguinity is specified in 499 patients and is present in 49.30\% of cases, the geographical origin of patients is variable, 53\% are from the center of the country and 43\% from the east. The circumstances of the diagnosis are known in 87.25\% of subjects, these are clinical symptoms in 93.91\% of patients, with an average age at diagnosis of 16.31 months for MT and 5.5 years for IT. The diagnosis is neonatal in only 5.68\% of cases. Blood cells transfusion needs are known in 80\% of our cohort, 86\% receive a systematic and regular diet; 554 patients are on chelation therapy, the main modality being deferoxamine or Deferasirox type monotherapy. 40 MT patients received Hematopoetic Stem Cell Transplantation. The monitoring of iron overload was based mainly on the determination of ferritinemia, only 8.8\% of patients received cardiac and hepatic MRI. Various complications associated with iron overload have been reported, the most common being: Hepatic injury (48\%), heart disease (36\%), diabetes (30\%), hypothyroidism (29.17). \%), with average ages of onset of 26.67, 18, 19, and 14.50 years, respectively. In addition, viral serology was performed in 536 patients, 64 (11.9\%) of whom were carriers of anti-HCV Ab. Conclusion\&nbsp;:\&nbsp;The quality and life expectancy of thalassemic patients has improved significantly in recent years; complications related to iron overload remain the leading cause of death, the means of evaluation remain insufficient in our country. In addition, the care of our patients must be standardized on the national territory. Disclosures No relevant conflicts of interest to declare.},
	author = {Grifi, Fatiha and Djenouni, A. and Bougherira, S. and Abad, MT and Boucherit, C. and Boudjerra, N. and Zidani, N. and Aboura, C. and Aribi, A. and Belhani, M. and Nekkal, S. and Bouaricha, H. and Benhassine, Fz and Nacer, R. Ahmed and Tensaout, F. and Ait-amer, N. and Hamladji, RM and Hamdi, S and Benakli, Malek}
}
@article {65551,
	title = {Descriptive Study of Diffuse Large B Cell Lymphoma in Algeria and Tunisia over a Period of 5 Years},
	journal = {BloodBlood},
	volume = {128},
	year = {2016},
	month = {2016},
	pages = {5412},
	abstract = {Background: Diffuse Large B Cell Lymphoma (DLBCL) is the most common form of aggressive non-Hodgkin{\textquoteright}s lymphoma (NHL) accounting for approximately 40 \% of all NHL cases. The aim of our study is to carry out an epidemiologic description and to compute the incidence of DLBCL in 2North African countries, Algeria and Tunisia. Patients and methods: This is a multicenter retrospective and descriptive study, covering a period of 5 years (January 2010 - December 2014), carried out in 17 centers in Algeria and 5 centers in Tunisia. Patients aged less than 15 years were excluded. We used the classification of World Health Organization. We used Epi info 6 software to analyze the data. Results: 1432 cases were identified, 1175 in Algeria and 257 in Tunisia. The sex distribution of DLBCL was as follows: males 837 (58.4 \%), females 591 (41.6 \%), male-to-female ratio 1.40. The age of patients ranged from 16 to 96 years (median 52 years) and 64.2 \% of the patients are less than 60. The incidence estimates for the years 2012 and 2013 are respectively 0.86 and 0.87 for 100,000 inhabitants. The most frequent occupation of the cases is farmworker (11.5\%). The average time between the date of diagnosis and clinical examination is 31 days. The average delay between the first clinical sign and the date of diagnosis is 133 days. A familial history of cancer is found in 10\% of the cases. The lymph node biopsy was undertaken in 30.7\% of the cases in the cervical area and in 15\% of cases in the mediastinal area. A reexamination of the slides was undertaken in 20\% of cases while 61.6\% of them were found to be advanced clinical stages (III + IV). Splenomegaly was found in 16\% of the cases and hepatomegaly in 7\%. ORL damage was found in 16\% of the cases and marrow infiltration in 10.2\%. A Prognostic Score IPI >= 2 is found in 38\% of the patients. Comments:\&nbsp;On a previous Algerian study concerning all lymphomas diagnosed over a period of 6 years (2007-2012) (Journal of Hematology No. 10-11, 2015), 485 new cases of lymphoma were diagnosed on average per year. In the present study, the average number of new cases of DLBCL was 235 and the average proportion was 48\% of all lymphomas. It should be emphasized that all cases underwent an immunohistochemical study and that lymphatic cases were excluded (digestive, bone, skin). The national incidence rate is low compared to that of international studies, a fact that is probably due to difficulties in the diagnosis including lack of implementation of immunohistochemistry techniques in our region. Disclosures No relevant conflicts of interest to declare.},
	author = {Boudjerra, N. and Oukid, S. and Abad, MT and Aboura, C. and Louanchi, L. and Ramaoun, M. and Belhani, M. and Allouda, M. and Aftisse, H. and Ait-Ali, H. and lakhal, R. Ben and Meddeb, B. and Ait-Ameur, N. and Belhadri, F. and Tensaout, F. and Nacer, R. Ahmed and Hamladji, RM and Bougherira, S. and Benakli, Malek}
}
